Former Cantel Medical CEO to Take Helm at Ivenix

Ivenix Inc. has appointed Jorgen B. Hansen as CEO and a member of Ivenix’s board of directors. Hansen has more than 25 years of global healthcare experience.

The CEO appointment comes at a time of great momentum for Ivenix, which received its 510(k) clearance from the U.S. Food and Drug Administration (FDA) in 2019. The infusion system was cleared under the FDA’s new regulatory guidance, adopted in 2014 to address recurring safety problems associated with existing infusion pumps.
 
“We are thrilled to have someone of Jorgen’s caliber leading Ivenix as we build our business and execute our market launch,” said Ivenix Board Chairman John Douglass. “Jorgen brings extensive market knowledge, strategy, product and business development experience at this important time in the company’s evolution. He is a proven medical technology leader with deep expertise in commercialization strategies that successfully drive company growth.”
 
Prior to joining Ivenix, Hansen spent seven years serving in leadership positions at the fast-growing Cantel Medical Corporation, most recently as president and CEO, heading the company’s organic growth globally and overseeing the execution of more than 25 acquisitions. Before that, he served as senior vice president for global strategy and marketing, business development, science and innovation at ConvaTec. Hansen also held leadership roles at Coloplast A/S, including as senior vice president of global operations, business unit head and general manager in China.

Hansen earned degrees in mechanical engineering from the Denmark Technical University and international commerce from the Copenhagen Business School.
 
“I am incredibly excited about the opportunity to join Ivenix, especially given the company’s powerful momentum following FDA clearance of its novel infusion system,” said Hansen. “The technology has massive market potential and I look forward to leading the company to realize its vision of eliminating infusion errors, improving patient outcomes and reducing related healthcare costs.”
 
Last June, the FDA issued its 510(k) clearance for the Ivenix Infusion System, which is touted as the first and only large-volume pump and infusion system designed from the ground up to meet the new FDA infusion pump guidelines adopted in 2014 to address the recurring safety problems associated with infusion pumps.

The cleared Ivenix Infusion System includes:

• A large-volume infusion pump with a smartphone-like user interface, advanced pumping technology that measures flow to maximize accuracy, and a system that is able to anticipate and prevent critical use errors;
• A portfolio of administration sets to accommodate the diverse infusion needs of healthcare organizations; and
• An infusion management suite of end-to-end administration tools, applications and analytics to remotely monitor infusions and proactively manage improvements.